Anonymous
Guest
Anonymous
Guest
When does the patent expire for Evista?
Who cares? It doesn't sell.
I believe the 70s pornstar in the Axiron advert will keep us all employed through 2014 and maybe beyond.
Axiron is growing and will probably be a 750 million a year product...that is all pc reps need.
Okay,
How much does Androgel sell per year? How many reps do they have. Are you a moron=Axiron by itself will not warant a full sales force. Maybe if you add Cialis.
okay,You sound like the idiot. We aren't losing Cialis for many years. Look for little reduction in NSPC, NSR, Mens Health and Diabetes. Cuts to MSK-PC and Cardio big time.
PS-Effient is actually doing well(okay,giant on the short bus) so I do not think cuts will come here. They are mean and lean.okay,
When is the last time you sold Cialis daily???? How much do you sell of the daily or better yet, how much of cialis is daily? Reps are doing shit for daily.DTC is selling cialis.
okay,
When is the last time you sold Cialis daily???? How much do you sell of the daily or better yet, how much of cialis is daily? Reps are doing shit for daily.DTC is selling cialis.
idiot??? Look at the reports and then tell me how reps help. As needed only has DTC advertisements and samples and it is the lion's share of the market. Take your relationships and shove it! Also, DTC for daily is probably making you look good.Cialis daily is growing...do you even work in this division or at Lilly. DTC helps but relationships, samples, service, formulary coverage/availability, indications all help to. Cialis is a huge product revenue wise.
And Effient isn't doing well...the revenue vs. expense (plus the fact that we don't own the product outright) makes that area prime for cuts.
idiot??? Look at the reports and then tell me how reps help. As needed only has DTC advertisements and samples and it is the lion's share of the market. Take your relationships and shove it! Also, DTC for daily is probably making you look good.
Effient is looking great with the financial community. It is actually a high on our 2nd Quarter reports.